Otsuka Pharmaceutical announced that the FDA is reviewing investigational centanafadine -- a potential first-in-class ...

As of 1 February 2026, changes to New Zealand's prescribing rules for Attention-Deficit Hyperactivity Disorder (ADHD) ...

Under the new rules, GPs and nurse practitioners can prescribe the publicly funded stimulant medicines for ADHD that are currently available. These include methylphenidate, dexamfetamine and ...

Doctors fear over-diagnosis, but advocates says it's a big step in improving access to help.

Under the new rules, clinicians can prescribe publicly funded ADHD stimulant medicines, including methylphenidate, dexamfetamine, and lisdexamfetamine. Dr Russell notes that global shortages of ADHD ...

ADHD diagnosis, which largely originated in the United States, began to spread to the rest of the globe in the late 1990s, ...

Adam Currie - who already had his diagnosis - said his Monday morning appointment was "really smooth".

The FDA has started a priority review of Otsuka Pharma's triple-acting drug for attention-deficit hyperactivity disorder ...

States are continuing to shake up the way a prevalent developmental disorder is treated by allowing more health professionals ...

ADHD is associated with impulsivity, hyperactivity, and trouble with focus, but kids with ADHD may also struggle with motor ...

Changes proposed by the Allan government will seek to cut down a process that can take up to a year and costs at least $2000.

Substance use disorders result when the body becomes addicted to drugs or alcohol. Though addiction itself is a chemical ...